FY25 revenue consensus $2.79B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $184 from $182 at BofA
- Neurocrine price target raised to $185 from $170 at Morgan Stanley
- NBIX Upcoming Earnings Report: What to Expect?
- Neurocrine price target raised to $176 from $162 at UBS
- Neurocrine initiates Phase 3 registrational program for osavampator in MDD